C. Alves

Assessing mNIS+7Ionis and international neurologists' proficiency in a familial amyloidotic polyneuropathy trial

S. Ayache, R. Bergemann, W. Litchy, 2017, Muscle & nerve.

Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis

J. Kelly, S. Cavaco, J. Fernandes, 2018, Journal of Neurology.

Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study

E. Nordh, Yi-Chung Lee, R. Sommerville, 2020, Lancet Neurology.

A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR MET 30 and TTR MET 119

T. Coelho, Almeida, P. Costa, 1993 .

Predictors of cognitive dysfunction in hereditary transthyretin amyloidosis with liver transplant

A. Teixeira-Pinto, S. Cavaco, J. Fernandes, 2022, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

Patisiran treatment in patients with hereditary transthyretin‐mediated amyloidosis with polyneuropathy after liver transplantation

E. Nordh, R. Orrell, S. Ayache, 2022, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Domino Liver Transplantation (DLT) and De Novo Familial Amyloid Polyneuropathy (FAP): The Portuguese Experience (S58.004).

T. Coelho, A. Guimarães, J. Daniel, 2013, Neurology.

Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Karla P. Zepeda, Hansie M Mathelier, J. Felius, 2023, Neurology and Therapy.

Familial Amyloid Polyneuropathy treatment with Tafamidis – evaluation of one- and two-year treatment in Porto, Portugal

T. Coelho, Márcio Cardoso, C. Alves, 2015, Orphanet Journal of Rare Diseases.